IE
GRCE

Israel Englander’s Grace Therapeutics GRCE Stock Holding History

Israel Englander’s Portfolio GRCE Stock Details GRCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-780
Closed -$21K – 7344
2021
Q2 		$21K Buy
+780
New +$19K ﹤0.01% 6428
2021
Q1 		– Sell
-783
Closed -$12K – 6591
2020
Q4 		$12K Buy
+783
New +$9.05K ﹤0.01% 5141
2020
Q1 		– Sell
-803
Closed -$94K – 4608
2019
Q4 		$94K Buy
+803
New +$79.3K ﹤0.01% 4038

Other funds holding GRCE

Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TSS
Two Sigma Securities New York $1.16B AUM 36.23% 1-Year Est. Return
EDRH
Edmond de Rothschild Holding Chambesy, Switzerland $7.59B AUM 23.44% 1-Year Est. Return
SIAP
Sterling Investment Advisors (Pennsylvania) Berwyn, Pennsylvania $599M AUM 28.66% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Israel Englander's GRCE Position: Q3 2021 in Review

Israel Englander sold out of Grace Therapeutics (GRCE) in Q3 2021, closing a stake of 780 shares — an estimated $21K sold.

Israel Englander first reported a position in GRCE in Q4 2019 and held it in 3 quarters. The position peaked at $94K in Q4 2019. 17 funds tracked by Wall St. Rank hold GRCE as of Q3 2021.

  • Israel Englander reported no remaining Grace Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Israel Englander sold 780 Grace Therapeutics shares in Q3 2021, an estimated $21K.
  • Israel Englander first reported a position in Grace Therapeutics in Q4 2019 and held it in 3 quarters.
  • Israel Englander's Grace Therapeutics position peaked at $94K in Q4 2019.
  • 17 funds tracked by Wall St. Rank held Grace Therapeutics as of Q3 2021.

Based on Millennium Management's 13F filing for Q3 2021, filed 15 Nov 2021.